 | |
| Type | Subsidiary |
|---|---|
| Industry | Bioelectronics |
| Founded | November 2016 [1] |
| Founders | [2] |
| Headquarters | , |
Key people | Kristoffer Famm (President) [4] |
| Parent | GlaxoSmithKline (55% equity interest) [3] |
| Website | galvani |
Galvani Bioelectronics is a Stevenage, United Kingdom-based [5] bioelectronics R&D company.
It was founded by Alphabet Inc. subsidiary Verily Life Sciences and British pharmaceutical company GlaxoSmithKline (GSK) in November 2016. [1] [2] The partnership to form the company was announced on 1 August 2016. [3]
Verily has a 45% equity interest, while GSK has a 55% equity interest, making GSK the effective owner. [3] The initial agreed upon investment between the two companies is up to £540 million over a period of seven years [3] [6] and will be used "to develop prototype devices aimed at controlling a variety of chronic conditions." [7] Additionally, both companies agreed to contribute their existing intellectual property rights.
In November 2021, a team of laparoscopic surgeons successfully completed the first implantation of a Galvani device in a patient. [8]
Ribena is a brand of blackcurrant-based soft drink, and fruit drink concentrate designed to be mixed with water. It is available in bottles, cans and multi-packs. Originally of British origin, it was produced by British pharmaceutical company GlaxoSmithKline (GSK) until 2013, when the brand was sold to Japanese beverage conglomerate Suntory.
GSK plc, is a British multinational pharmaceutical and biotechnology company with global headquarters in London. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, GSK is the tenth largest pharmaceutical company and #294 on the 2022 Fortune Global 500, ranked behind other pharmaceutical companies China Resources, Sinopharm, Johnson & Johnson, Pfizer, Roche, AbbVie, Novartis, Bayer, and Merck Sharp & Dohme.
Horlicks is a sweet malted milk hot drink powder developed by founders James and William Horlick. It was first sold as "Horlick's Infant and Invalids Food", soon adding "aged and travellers" to their label. In the early 20th century, it was sold as a powdered meal replacement drink mix.
Rosiglitazone is an antidiabetic drug in the thiazolidinedione class. It works as an insulin sensitizer, by binding to the PPAR in fat cells and making the cells more responsive to insulin. It is marketed by the pharmaceutical company GlaxoSmithKline (GSK) as a stand-alone drug or for use in combination with metformin or with glimepiride. First released in 1999, annual sales peaked at approximately $2.5-billion in 2006; however, following a meta-analysis in 2007 that linked the drug's use to an increased risk of heart attack, sales plummeted to just $9.5-million in 2012. The drug's patent expired in 2012.
Smith, Kline & French (SKF) was an American pharmaceutical company.
Sir Andrew Philip Witty is a British business executive, who is the current chief executive officer (CEO) of UnitedHealth Group. He was also the CEO of GlaxoSmithKline between 2008 and 2017. He formerly held the role of chancellor of the University of Nottingham.
GlaxoSmithKline Pakistan is a Pakistani pharmaceutical company which is a subsidiary of British company GSK. It is the largest pharmaceutical company in Pakistan.
Sirtris Pharmaceuticals, Inc. was a biotechnology company based in Cambridge, MA that developed therapies for type 2 diabetes, cancer, and other diseases. Conceived in 2004 by Harvard University biologist David Sinclair and serial entrepreneur Andrew Perlman, and founded that year by Sinclair and Perlman, along with Christoph Westphal, Richard Aldrich, Richard Pops, and Paul Schimmel, the company was focused on developing Sinclair's research into activators of sirtuins, work that began in the laboratory of Leonard P. Guarente where Sinclair worked as a post-doc before starting his own lab.
Stiefel Laboratories is an American dermatological pharmaceutical company, with its global headquarters in Research Triangle Park, North Carolina. It makes products such as Duac and Oilatum. Stiefel was acquired by GlaxoSmithKline at a price of $2.9 billion. The company was founded in 1847 by John David Stiefel, Ferdinand von Hebra and Paul Unna, who initially created medicated soaps.
The pharmaceutical industry in the United Kingdom directly employs around 73,000 people and in 2007 contributed £8.4 billion to the UK's GDP and invested a total of £3.9 billion in research and development. In 2007 exports of pharmaceutical products from the UK totalled £14.6 billion, creating a trade surplus in pharmaceutical products of £4.3 billion.
Canada v GlaxoSmithKline Inc is the first ruling of the Supreme Court of Canada that deals with issues involving transfer pricing and how they are treated under the Income Tax Act of Canada ("ITA").
Francesco De Rubertis is a partner at medicxi, a venture capital firm with offices in London, Jersey and Geneva, having co-founded the firm in February 2016. Prior to that he was a partner at another venture capital firm, Index Ventures, having led the firm's efforts to establish its life sciences practice after joining in 1997.
Verily Life Sciences LLC, also known as Verily, is Alphabet Inc.'s research organization devoted to the study of life sciences. The organization was formerly a division of Google X, until August 10, 2015, when Sergey Brin announced that the organization would become an independent subsidiary of Alphabet Inc. with restructuring completed on October 2, 2015. On December 7, 2015, Google Life Sciences was renamed Verily.
Study 329 was a clinical trial which was conducted in North America from 1994 to 1998 to study the efficacy of paroxetine, an SSRI anti-depressant, in treating 12- to 18-year-olds diagnosed with major depressive disorder. Led by Martin Keller, then professor of psychiatry at Brown University, and funded by the British pharmaceutical company SmithKline Beecham—known since 2000 as GlaxoSmithKline (GSK)—the study compared paroxetine with imipramine, a tricyclic antidepressant, and placebo. SmithKline Beecham had released paroxetine in 1991, marketing it as Paxil in North America and Seroxat in the UK. The drug attracted sales of $11.7 billion in the United States alone from 1997 to 2006, including $2.12 billion in 2002, the year before it lost its patent.
Dame Emma Natasha Walmsley is the chief executive officer (CEO) of GlaxoSmithKline. She succeeded Sir Andrew Witty, who retired in March 2017. Before GSK, she worked for L'Oréal for 17 years, and was a non-executive director of Diageo until September 2016. She grew up in Barrow-in-Furness, Cumbria, England.
Paul-Peter Tak is an immunologist and academic specialising in the fields of rheumatology and immunology. In addition to academic research, he served as an executive of several pharmaceutical companies.
The New Frontiers Science Park is a science park in Essex, on a redeveloped research site of GlaxoSmithKline (GSK).
Simon Paul Dingemans is an English former banker and businessman. Until May 2019 he was chief financial officer at GlaxoSmithKline. In July 2019 he was appointed chair of the Financial Reporting Council, and was set to lead its transition into the Audit, Reporting and Governance Authority, but left in May 2020.
Moncef Mohamed Slaoui is a Moroccan-born Belgian-American researcher who served as the head of Operation Warp Speed (OPWASP) under President Donald Trump from 2020 to 2021.
The GlaxoSmithKline Carbon Neutral Laboratory for Sustainable Chemistry is a chemistry laboratory in Nottingham, England. It is located on the Jubilee Campus of the University of Nottingham, and is part of the university's School of Chemistry. The school carries out research at the carbon neutral laboratory, which is the first of its kind in the UK. The construction was majority funded by GlaxoSmithKline, as part of their commitment to green chemistry first announced in 2010, and saw a grant of £12 million provided to the project.
 | This article about a company of the UK is a stub. You can help Wikipedia by expanding it. |